

Supplementary Table 1: Stratified Analyses* of Personal and Clinical Social Support and Discontinuation of AET (N=2,687)

	% with outcome	Personal Social Support Categories			P**	P†
		High	Moderate	Low		
Age						
< 60 years of age, N		503	471	385		
HR	22%	1.00	1.15	1.11	.54	.28
95% CI			(0.87-1.52)	(0.82-1.48)		
>= 60 years of age, N		455	451	422		
HR	26%	1.00	1.26	1.41	.02	
95% CI			(0.96-1.65)	(1.07-1.84)		
Race/ethnicity						
White, N		735	687	589		
HR	25%	1.00	1.20	1.26	.05	.83
95% CI			(0.97-1.49)	(1.01-1.57)		
AA, API, Hispanic, Other, N‡		223	235	218		
HR	21%	1.00	1.06	1.45	.07	
95% CI		735	687	589		
Level of Education						
Some college or less, N		485	426	379		
HR	27%	1.00	1.29	1.38	.02	.72
95% CI			(1.00-1.67)	(1.06-1.80)		
College graduate or more, N		473	496	426		
HR	21%	1.00	1.08	1.13	.42	
95% CI			(0.81-1.44)	(0.84-1.51)		
Stage						
Early stage, N		870	839	726		
HR	25%	1.00	1.20	1.28	.02	.94
95% CI			(0.98-1.47)	(1.04-1.57)		
Late stage, N		88	83	81		
HR	20%	1.00	1.11	1.14	.74	
95% CI			(0.53-2.33)	(0.53-2.45)		
Type of endocrine therapy						
Tamoxifen-only, N		228	209	177		
HR	26%	1.00	1.25	1.40	.11	.88
95% CI			(0.85-1.85)	(0.93-2.10)		
AI-only, N		555	523	476		
HR	24%	1.00	1.13	1.31	.03	
95% CI			(0.87-1.46)	(1.02-1.69)		
Both tamoxifen and AI, N		175	190	154		
HR	24%	1.00	1.34	1.42	.19	
95% CI			(0.85-2.12)	(0.86-2.33)		
Presence of menopausal symptoms						

No, N		308	281	209		
HR	23%	1.00	1.22	1.42	.07	.61
95% CI			(0.86-1.75)	(0.97-2.07)		
Yes, N		650	641	598		
HR	26%	1.00	1.17	1.26	.05	
95% CI			(0.93-1.47)	(1.01-1.59)		
Presence of comorbidities						
No, N		812	762	661		
HR	25%	1.00	1.26	1.30	.02	.78
95% CI			(1.02-1.54)	(1.05-1.61)		
Yes, N		67	92	86		
HR	25%	1.00	0.94	1.21	.51	
95% CI			(0.46-1.92)	(0.62-2.34)		
Presence of Depressive Symptoms						
Low presence, N		619	500	298		
HR	16%	1.00	1.19	1.12	.41	.83
95% CI			(0.92-1.54)	(0.83-1.51)		
High presence, N		334	417	500		
HR	27%	1.00	1.16	1.22	.19	
95% CI			(0.87-1.60)	(0.92-1.63)		


		% with outcome	Clinical Social Support Categories			P**	P†
			High	Moderate	Low		
Age							
< 60 years of age, N		503	471	385			
HR	22%	1.00	1.15	1.37	.03	.98	
95% CI			(0.86-1.54)	(1.04-1.81)			
>= 60 years of age, N		455	451	422			
HR	26%	1.00	1.16	1.36	.02		
95% CI			(0.89-1.51)	(1.03-1.79)			
Race/ethnicity							
White, N		735	687	589			
HR	25%	1.00	1.12	1.27	.05	.37	
95% CI			(0.91-1.40)	(1.03-1.58)			
AA, API, Hispanic, Other, N‡		223	235	218			
HR	21%	1.00	1.36	1.55	.04		
95% CI			(0.87-2.12)	(1.05-2.29)			
Level of Education							
Some college or less, N		485	426	379			
HR	27%	1.00	1.67	1.32	.03	.78	
95% CI			(1.02-1.71)	(1.02-1.71)			
College graduate or more, N		473	496	426			
HR	21%	1.00	1.17	1.42	.02		

	95% CI			(0.87-1.57)	(1.07-1.87)		
Stage							
Early stage, N	25%	870	839	726			
HR		1.00	1.21	1.39	<.01	.72	
95% CI			(0.99-1.47)	(1.14-1.68)			
Late stage, N	20%	88	83	81			
HR		1.00	0.73	1.02	.85		
95% CI			(0.33-1.60)	(0.49-2.11)			
Type of endocrine therapy							
Tamoxifen-only, N		228	209	177			
HR	26%	1.00	1.89	1.74	<.01	.89	
95% CI			(1.24-2.86)	(1.16-2.61)			
AI-only, N		555	523	476			
HR	24%	1.00	1.06	1.42	<.01		
95% CI			(0.81-1.37)	(1.11-1.82)			
Both Tamoxifen and AI, N		175	190	154			
HR	24%	1.00	0.91	0.91	.62		
95% CI			(0.58-1.43)	(0.58-1.43)			
Presence of menopausal symptoms							
No menopausal symptoms, N		308	281	209			
HR	23%	1.00	1.13	1.36	.03	.96	
95% CI			(0.77-1.67)	(0.94-1.96)			
Menopausal symptoms, N		650	641	598			
HR	26%	1.00	1.67	1.36	.01		
95% CI			(0.93-1.46)	(1.09-1.70)			
Presence of comorbidities							
No, N		812	762	661			
HR	25%	1.00	1.17	1.36	<.01	.58	
95% CI			(0.95-1.50)	(1.11-1.67)			
Yes, N		67	92	86			
HR	25%	1.00	0.86	1.31	.44		
95% CI			(0.44-1.70)	(0.68-2.52)			
Presence of Depressive Symptoms							
Low presence, N		619	500	298			
HR	16%	1.00	1.18	1.34	.04	.37	
95% CI			(0.90-1.55)	(1.04-1.77)			
High presence, N	27%	334	417	500			
HR		1.00	1.05	1.19	.17		
95% CI			(0.79-1.39)	(0.92-1.54)			

*Models adjusted for Model 2 covariates except for stratified variable

**p-value, test for trend; †p-value, test for interaction

‡AA=African-American, API=Asian/Pacific Islander



Supplementary Figure 1: Proportion of Noninitiation, Discontinuation, and Nonadherence to Adjuvant Endocrine Therapy by Level of Personal and Clinical Social Support (N=3,382*)

*Analyses of outcomes of discontinuation and nonadherence included 2,687 women who initiated treatment and filled at least two prescriptions.